X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LP-410 is designed to target the underlying mechanisms of Oral Graft-Versus-Host Disease (GVHD), potentially providing a safe and effective treatment option for affected individuals.
Lead Product(s): LP-410
Therapeutic Area: Immunology Product Name: LP-410
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2024
Details:
LP-310 is a oral rinse formulation of LP-10, which is act as Increased local concentration in oral cavity while minimalizing systemic toxicity, which is investigated for the treatment of Graft-versus-Host Disease.
Lead Product(s): Liposomal Tacrolimus
Therapeutic Area: Immunology Product Name: LP-310
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
LP-310 is a oral rinse formulation of LP-10, which is act as Increased local concentration in oral cavity while minimalizing systemic toxicity, which is investigated for the treatment of oral Lichen Planus.
Lead Product(s): Liposomal Tacrolimus
Therapeutic Area: Immunology Product Name: LP-310
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Details:
The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.
Lead Product(s): Tacrolimus
Therapeutic Area: Urology Product Name: LP-10
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Cook MyoSite
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 17, 2023
Details:
LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. The product candidate is currently in Phase 2a clinical trial.
Lead Product(s): Tacrolimus
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: LP-10
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
A multi-site, prospective, open-label, dose-escalation clinical trial assessing the safety and efficacy of LP-10 (liposomal tacrolimus) is now open for recruitment at several sites.
Lead Product(s): Tacrolimus
Therapeutic Area: Urology Product Name: LP-10
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
